<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Somatostatin and its analogues bind to somatostatin receptors (sst) 1 through 5 that are overexpressed in <z:hpo ids='HP_0100634'>neuroendocrine neoplasms</z:hpo> such as gastroenteropancreatic (GEP) <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>After ligand-receptor binding, a fraction of the ligand-receptor complexes internalize </plain></SENT>
<SENT sid="2" pm="."><plain>This internalization process is an effective means of delivering cytotoxic radiolabeled somatostatin analogues, especially those emitting short-range decay particles such as Auger electrons, to the neoplastic cell nucleus </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="30430">Indium</z:chebi>-111-pentetreotide, an sst 2 preferring somatostatin analogue with gamma and Auger electron decay characteristics, is commonly used for the scintigraphic evaluation and management of neuroendocrine <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>This clinical trial was performed to determine the effectiveness and tolerability of therapeutic doses of (111)In-pentetreotide in patients with GEP <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>GEP <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> patients who had failed <z:hpo ids='HP_0000001'>all</z:hpo> forms of conventional therapy, with worsening of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-related signs and symptoms and/or radiographically documented progressive disease, an expected survival less than 6 months, and sst positivity as determined by the uptake on a 6.0 mCi (111)In-pentetreotide scan (OctreoScan; Mallinckrodt Medical, Inc, St </plain></SENT>
<SENT sid="6" pm="."><plain>Louis, MO), were treated with at least 2 monthly 180-mCi intravenous injections of (111)In-pentetreotide </plain></SENT>
<SENT sid="7" pm="."><plain>Baseline clinical assessments, serum chemistries, and plasma pancreastatin levels were measured and repeated before each (111)In-pentetreotide treatment </plain></SENT>
<SENT sid="8" pm="."><plain>From February 1997 to February 1998, 27 GEP (24 <z:hpo ids='HP_0100570'>carcinoid</z:hpo> <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with <z:hpo ids='HP_0100570'>carcinoid</z:hpo> syndrome and 3 pancreatic islet cells) patients were accrued, with 26 patients evaluable for clinical and radiographic responses, 21 patients evaluable for biochemical assessments, and 27 patients evaluable for survival analysis and safety </plain></SENT>
<SENT sid="9" pm="."><plain>Toxicity was evaluated by using standard National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute (NCI) Common Toxicity Criteria guidelines </plain></SENT>
<SENT sid="10" pm="."><plain>Clinical benefit occurred in 16 (62%) patients </plain></SENT>
<SENT sid="11" pm="."><plain>Pancreastatin levels decreased by 50% or more in 81% of the patients </plain></SENT>
<SENT sid="12" pm="."><plain>Objective partial radiographic responses occurred in 2 (8%) patients, and significant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> (defined by 20 Hounsfield units or greater decrease from baseline) developed in 7 (27%) patients </plain></SENT>
<SENT sid="13" pm="."><plain>The following transient Grades 3/4 NCI Common Toxicity Criteria side effects were observed, respectively: leukocyte: 1/1; platelets: 0/2; <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>: 3/0; <z:chebi fb="0" ids="16990">bilirubin</z:chebi>: 1/3; <z:chebi fb="0" ids="16737">creatinine</z:chebi>: 1/0; neurologic: 1/0 </plain></SENT>
<SENT sid="14" pm="."><plain><z:mpath ids='MPATH_512'>Myeloproliferative disease</z:mpath> and/or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> have not been observed in the 6 patients followed-up for 48+ months </plain></SENT>
<SENT sid="15" pm="."><plain>The median survival was 18 months (range, 3-54+ mo) </plain></SENT>
<SENT sid="16" pm="."><plain>Two doses (180 mCi) of (111)In-pentetreotide are safe, well-tolerated, and improve symptoms in 62% of patients, decrease hormonal markers in 81% of patients, decrease Hounsfield units on computed tomography (CT) scans in 27% of patients, with 8% partial radiographic responses and increased expected survival in GEP <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients with somatostatin receptor-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>The maximal tolerated dose of (111)In-pentetreotide and the optimal dosing schedules remain under investigation </plain></SENT>
</text></document>